Canaccord Genuity Downgrades GreenLight Biosciences (GRNA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500, Nasdaq pare declines as AI rout teeters; healthcare, staples gain
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts GRNA Hot Sheet
Price: $0.30 --0%
Rating Summary:
0 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 12 | New: 31
Rating Summary:
0 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 12 | New: 31
Join SI Premium – FREE
Canaccord Genuity analyst Bobby Burleson downgraded GreenLight Biosciences (NASDAQ: GRNA) from Buy to Hold with a price target of $0.30 (from $4.00).
For an analyst ratings summary and ratings history on GreenLight Biosciences click here. For more ratings news on GreenLight Biosciences click here.
Shares of GreenLight Biosciences closed at $0.29 yesterday.
You May Also Be Interested In
- Deutsche Bank Upgrades JCDecaux SA (DEC:FP) (JCDXF) to Buy
- Stellantis NV (STLA:IM) (STLA) PT Lowered to EUR4.50 at Deutsche Bank
- Temenos AG (TEMN:SW) (TMSNY) PT Raised to CHF73 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
